Research Research Programs Biotechnology, Imaging & Drug Development Systems, Pathways & Targets Cancer Control Clinical Research Stern Center for Cancer Clinical Trials and Research Disease-Oriented Teams Protocol Review and Monitoring Committee Research Resources Membership Guidelines Shared Resources Funding Opportunities Acknowledgement of Grant and Shared Resources Centers & Institutes Anti-Cancer Challenge Research Anti-Cancer Challenge RFP Anti-Cancer Challenge Past Awardees Team Funds Disease-Oriented Teams Home Research Clinical Research Disease-Oriented Teams Disease-Oriented Teams are multidisciplinary groups of basic, translational, clinical, and population health investigators who collaborate on a specific cancer area in order to further the translation of CFCCC discoveries through the pipeline towards interventional clinical trials. As the first component of the CFCCC’s two-step clinical research review process, the focus of the DOTs is to ensure rigorous internal scientific review of protocols, curate the clinical trial portfolio, and drive innovation. What Does a DOT Do? Through their collective expertise, DOTs steward the Cancer Center's clinical research efforts, managing the clinical trials portfolio around the following principles: scientific merit, soundness of trial design, accrual potential, and likelihood for correlative translational science. Facilitate the translation of scientific discoveries to address specific types of cancer Promote multidisciplinary collaboration to address disease-specific questions Determine interest in and commitment to a trial and the potential to accrue Ensure adequate internal review of scientific quality and feasibility of clinical trials, and oversees prioritization of protocols Review clinical research portfolio and develops and brings forward new trials, including investigator-initiated trials Catalyze new multi-investigator, multidisciplinary preclinical and clinical translational research Submit a Protocol for Review All cancer-related hypothesis-drive clinical research studies must undergo a feasibility review by the corresponding DOT or Tumor Board. To submit a study for review, download and complete the application. Download Application Disease-Oriented Teams and Leadership Roster DOT Leader Breast Oncology Ritesh Parajuli, MD Devon Lawson, PhD Erin Lin, DO Gastrointestinal Oncology Jason Zell, DO Maheswari "Magi" Senthil, MD Genitourinary Oncology Edward Uchio, MD Michael McClelland, PhD Gynecologic Oncology Fabio Cappuccini, MD Lydia Su, PhD Hematologic Malignancies Angela Fleischman, MD, PhD Deepa Jeyakumar, MD Neuro-Oncology Daniela Bota, MD, PhD Frank Hsu, MD Skin Cancer Kenneth Linden, MD, PhD Bogi Andersen, MD Pancreatic-Hepatobiliary David Imagawa, MD, PhD Jennifer Valerin, MD, PhD Nadine Abi-Jaoudeh, MD Murray Korc, MD Tumor Boards At UCI, our tumor boards are a group of doctors and other health care providers with different specialties that meet regularly to discuss cancer cases and share knowledge. The board’s goal is to determine the best possible cancer treatment and care plan for an individual patient. Tumor Board Frequency Contact Neuro Oncology Weekly Naudia Chappell, email@example.com Breast UCIMC/Pacific Breast Weekly Naudia Chappell, firstname.lastname@example.org Gastrointestinal Weekly Naudia Chappell, email@example.com Genitourinary Bi-weekly Naudia Chappell, firstname.lastname@example.org Gynecologic Oncology Weekly Leticia Vazquez, email@example.com Head & Neck Weekly Andrea Desanto, firstname.lastname@example.org Hepatobiliary Weekly William To, email@example.com Lung Bi-weekly Naudia Chappell, firstname.lastname@example.org Malignant Hematology Bi-weekly Naudia Chappell, email@example.com Pigmented Lesion Monthly Naudia Chappell, firstname.lastname@example.org Sarcoma Bi-weekly Naudia Chappell, email@example.com Join a DOT Please contact us at CancerCenter_Committees1@hs.uci.edu to learn more.